Skip to main content

Table 1 Characteristics of 32 CML patients according to treatment-free remission (TFR) or molecular relapse after imatinib discontinuation

From: Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients

  Patients in TFR no. 19 (59 %)   Relapsed patients no. 13 (41 %)   p
Age at diagnosis (mean, range) 74 (47–88)   56 (37–77)   0.004
Leukocytes at diagnosis ×103/uL (mean, range) 50.47 (8.15–221)   69 (19.8–263)   ns
Platelets at diagnosis ×103/uL (mean, range) 472 (178–918)   357 (171–695)   ns
Months to CMR (median, range) 28 (3–88)   30 (6–93)   ns
Months of TKIs (median, range) 86 (24–127)   84 (45–143)   ns
Months of TKIs >60 (no., %) 13 68.4 12 92.3 ns
Male gender (no., %) 16 84.2 8 61.5 ns
Sokal risk (no., %)      
 Low 6 31.6 8 61.5 ns
 Intermediate 10 52.6 3 23.1 ns
 High 3 15.8 2 15.4 ns
First-line TKI treatment (no., %) 11 57.9 11 84.6 ns
Previous IFN treatment (no., %) 8 42.1 2 15.4 ns
Imatinib first-line TKI treatment (no., %) 19 100 13 100 ns
Nilotinib second-line TKI treatment (no., %) 1 5.3 1 7.7 ns
Age-corrected relative telomere length (mean ± SD) 0.01 ± 0.14   0.20 ± 0.21   0.01
  1. pres present, CMR complete molecular response, TKIs tyrosine kinase inhibitors, IFN interferon, ns not significant, SD standard deviation